$15.60
+1.3%SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Acceptable margins but limited operational leverage. Operating expense control is important.
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
SNWV โข NASDAQ
| SANUWAVE Health, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
44.1M | 32.6M | 20.4M | 16.7M | 13M | 4.1M | 1M | 1.9M | 738.5K | 1.4M | 965.5K | 847.4K | 800K | 769.2K | 802.6K | 728.4K | 660.7K | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||||||||
(11M) | (8.1M) | (6M) | (4.3M) | (5M) | (1.2M) | (538.9K) | (693.7K) | (242K) | (565.1K) | (285K) | (220K) | (189.8K) | (220.3K) | (261.9K) | (250.3K) | (225.8K) | (0.0) | (0.0) | (0.0) | |
33.1M | 24.6M | 14.4M | 12.4M | 8M | 2.9M | 489.8K | 1.2M | 496.6K | 810.9K | 680.5K | 627.4K | 610.2K | 549K | 540.7K | 478.1K | 434.9K | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||||||||||||
(28.1M) | (19.1M) | (14.9M) | (21.4M) | (22.2M) | (28.1M) | (9.3M) | (8.3M) | (4.3M) | (4.1M) | (5.2M) | (6.6M) | (6.6M) | (6.6M) | (9.3M) | (12.1M) | (9.1M) | (26.2K) | (34.1K) | (13.3K) | |
(26.8M) | (17.7M) | (13.6M) | (20M) | (20.3M) | (18.9M) | (8M) | (7.3M) | (3M) | (2.7M) | (2.7M) | (3.3M) | (4M) | (4.5M) | (6.3M) | (7.1M) | (5M) | (26.2K) | (34.1K) | (13.3K) | |
(1.4M) | (673K) | (579K) | (567K) | (1.1M) | (1.2M) | (1.2M) | (1.7M) | (1.3M) | (1.1M) | (2.2M) | (3M) | (2.3M) | (1.8M) | (2.7M) | (3.9M) | (3.4M) | (0.0) | (0.0) | (0.0) | |
4.9M | 5.4M | -540K | -9M | -14.1M | -25.2M | -8.8M | -7.2M | -3.8M | -3.3M | -4.4M | -6M | -6M | -6.1M | -8.8M | -11.8M | -8.7M | -26.2K | -34.1K | -13.3K | |
PRE-TAX INCOME | ||||||||||||||||||||
(6.2M) | (13.6M) | (15.6M) | (14.1M) | (7.1M) | (2.5M) | (1.8M) | (4.5M) | (1.1M) | (0.0) | (0.0) | (440.9K) | (2.5M) | (331.7K) | (472.2K) | (961.6K) | (739.8K) | (1.8K) | (35.0) | (240.0) | |
-6.2M | -13.6M | -15.6M | -14.1M | -7.1M | -2.5M | -1.8M | -4.5M | -1.1M | -855K | -399.8K | -453.7K | -2.5M | -331.7K | -472.2K | -961.6K | -739.8K | -306.8K | 0.0 | 0.0 | |
(0.0) | (789K) | (752K) | (766K) | (784K) | (8M) | (71.2K) | (10K) | (0.0) | (326.6K) | (310.4K) | (321K) | (326.3K) | (327.1K) | (325.8K) | (1.1M) | (671.9K) | (0.0) | (0.0) | (0.0) | |
7M | -36.8M | -25.3M | -1.3M | -13.1M | -5.7M | -1.6M | -4.5M | -1.7M | -3.1M | -372.5K | -10.6K | -6M | -339.2K | -1.4M | -3.4M | -536.2K | -359.4K | -35.0 | 36.9K | |
11.9M | -31.3M | -25.8M | -10.3M | -27.2M | -30.9M | -10.4M | -11.6M | -5.5M | -6.4M | -4.8M | -6M | -12M | -6.4M | -10.2M | -15.2M | -9.2M | -28.1K | -34.1K | 23.6K | |
NET INCOME | ||||||||||||||||||||
(86K) | (27K) | (4K) | (2K) | (28K) | (0.0) | (1.8M) | (45K) | (0.0) | (3.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -240K | -1.2M | -1.5K | (1.6K) | (1.6K) | |
11.8M | -31.4M | -25.8M | -10.3M | -27.3M | -30.9M | -10.4M | -11.6M | -5.5M | -6.4M | -4.8M | -6M | -11.3M | -6.4M | -10.2M | -14.9M | -6.2M | -26.6K | -35.7K | 22K |
SNWV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 13, 2026 | March 13, 2026 | 2026 | |
8-K/A 8-K/A 2025 (Amended) N/A | January 15, 2026 | August 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 07, 2025 | November 07, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Continue your SNWV research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.